Benzinga · Aug 27, 2026
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
AM
NASDAQ · AMLX
Amylyx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$34.49
Down-$0.53 (-1.54%)
Updated Sep 3, 2026, 11:36 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.26B
- P/E ratio
- -9.48
- Dividend yield
- 0.00%
- 52-week range
- $12.44 – $41.14
- Volume
- 1.94M
- Avg. volume
- 1.42M
Price performance
AMLX price history
1M range · 21 trading sessions · Daily adjusted prices
AMLX closed at $34.49 after 21 trading sessions, up 57.85% for the selected period.
- Last close
- $34.49
- Period change
- +57.85%
- Period low
- $21.43
- Period high
- $39.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $34.00 | $35.475 | $34.00 | $34.49 | 1.94M |
| Sep 1, 2026 | $33.49 | $34.21 | $32.99 | $33.81 | 1.82M |
| Aug 31, 2026 | $34.77 | $35.09 | $32.98 | $33.75 | 2.73M |
| Aug 28, 2026 | $36.78 | $37.68 | $34.475 | $34.74 | 1.36M |
| Aug 27, 2026 | $36.75 | $38.23 | $36.53 | $37.18 | 1.99M |
| Aug 26, 2026 | $37.13 | $37.69 | $35.79 | $37.08 | 2.82M |
| Aug 25, 2026 | $38.50 | $38.88 | $36.84 | $37.46 | 2.15M |
| Aug 24, 2026 | $38.64 | $39.38 | $37.45 | $38.15 | 3.71M |
| Aug 21, 2026 | $39.795 | $41.14 | $38.35 | $38.66 | 4.64M |
| Aug 20, 2026 | $37.49 | $40.4388 | $37.372 | $39.66 | 8.54M |
| Aug 19, 2026 | $36.13 | $39.07 | $35.3207 | $38.60 | 8.26M |
| Aug 18, 2026 | $29.91 | $35.39 | $28.00 | $35.11 | 23.98M |
| Aug 17, 2026 | $21.96 | $22.468 | $21.28 | $21.43 | 1.27M |
| Aug 14, 2026 | $22.35 | $22.39 | $21.29 | $21.63 | 1.59M |
| Aug 13, 2026 | $23.37 | $23.635 | $22.46 | $22.48 | 839.45K |
| Aug 12, 2026 | $23.86 | $24.0848 | $23.30 | $23.35 | 1.45M |
| Aug 11, 2026 | $22.78 | $23.7299 | $22.19 | $23.63 | 833.86K |
| Aug 10, 2026 | $22.68 | $23.03 | $22.00 | $22.67 | 1.33M |
| Aug 7, 2026 | $24.19 | $24.60 | $22.56 | $22.82 | 2.68M |
| Aug 6, 2026 | $21.10 | $24.36 | $21.10 | $24.19 | 3.54M |
| Aug 5, 2026 | $22.06 | $22.1694 | $21.52 | $21.85 | 1.77M |
Latest AMLX news
The latest Smart Investors Daily articles mentioning AMLX.
Stock researchCompany · Overview
AMLX research
Overview
Company profile and research snapshot.
Company profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Guggenheim | Buy | — |
| Aug 19, 2026 | Mizuho | Outperform | — |
| Aug 19, 2026 | Guggenheim | Buy | — |
| Aug 19, 2026 | Baird | Outperform | — |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
Benzinga · Aug 19, 2026
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.
Benzinga · Aug 19, 2026
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
